Search company, investor...
Tenaya Therapeutics company logo

Tenaya Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Tenaya Therapeutics

Tenaya Therapeutics (NASDAQ: TNYA) is a biopharmaceutical company dedicated to discovering and developing therapies for heart failure.

Headquarters Location

171 Oyster Point Blvd Suite 500

South San Francisco, California, 94080,

United States

Missing: Tenaya Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Tenaya Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Tenaya Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tenaya Therapeutics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Tenaya Therapeutics Patents

Tenaya Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Biotechnology
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



Latest Tenaya Therapeutics News

Tenaya Therapeutics GAAP EPS of -$0.61 beats by $0.03

Mar 8, 2023

Tenaya Therapeutics press release (NASDAQ: TNYA ): Q4 GAAP EPS of -$0.61 beats by $0.03. As of December 31, 2022, cash, cash equivalents and investments in marketable securities (current and noncurrent) were $204.2 million. Tenaya expects current cash, cash equivalents and investments in marketable securities (current and noncurrent) will be sufficient to fund the company into the first half of 2025. Recommended For You

Tenaya Therapeutics Frequently Asked Questions (FAQ)

  • When was Tenaya Therapeutics founded?

    Tenaya Therapeutics was founded in 2016.

  • Where is Tenaya Therapeutics's headquarters?

    Tenaya Therapeutics's headquarters is located at 171 Oyster Point Blvd, South San Francisco.

  • What is Tenaya Therapeutics's latest funding round?

    Tenaya Therapeutics's latest funding round is IPO.

  • How much did Tenaya Therapeutics raise?

    Tenaya Therapeutics raised a total of $248M.

  • Who are the investors of Tenaya Therapeutics?

    Investors of Tenaya Therapeutics include The Column Group, Google Ventures, Casdin Capital, Fidelity Investments, RA Capital Management and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.